Assembly Biosciences (NASDAQ:ASMB) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a strong-buy rating in a research report report published on Thursday,Zacks.com reports.

A number of other research firms also recently issued reports on ASMB. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a report on Friday, July 17th. Guggenheim reissued a “buy” rating and issued a $43.00 target price on shares of Assembly Biosciences in a research note on Thursday, May 28th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research report on Tuesday. Wall Street Zen lowered Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Mizuho set a $45.00 price objective on Assembly Biosciences and gave the stock an “outperform” rating in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $44.00.

Assembly Biosciences Price Performance

Shares of Assembly Biosciences stock opened at $34.38 on Thursday. Assembly Biosciences has a 1 year low of $20.23 and a 1 year high of $39.71. The firm has a market cap of $700.01 million, a PE ratio of 33.71 and a beta of 1.10. The company has a 50 day simple moving average of $27.11 and a two-hundred day simple moving average of $27.60.

Assembly Biosciences (NASDAQ:ASMB) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.52. The business had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. As a group, research analysts anticipate that Assembly Biosciences will post 2.28 earnings per share for the current year.

Institutional Investors Weigh In On Assembly Biosciences

A number of hedge funds have recently made changes to their positions in the business. Informed Momentum Co LLC boosted its stake in shares of Assembly Biosciences by 1.6% in the 4th quarter. Informed Momentum Co LLC now owns 29,523 shares of the biopharmaceutical company’s stock valued at $1,004,000 after purchasing an additional 451 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in shares of Assembly Biosciences by 4.2% during the 4th quarter. ADAR1 Capital Management LLC now owns 19,747 shares of the biopharmaceutical company’s stock valued at $672,000 after purchasing an additional 800 shares during the last quarter. Geode Capital Management LLC raised its position in Assembly Biosciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 131,307 shares of the biopharmaceutical company’s stock worth $4,468,000 after purchasing an additional 1,212 shares during the period. Arrowstreet Capital Limited Partnership raised its position in Assembly Biosciences by 4.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after purchasing an additional 1,634 shares during the period. Finally, Bank of America Corp DE raised its position in Assembly Biosciences by 6,382.7% in the 3rd quarter. Bank of America Corp DE now owns 3,371 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 3,319 shares during the period. 19.92% of the stock is currently owned by institutional investors.

Key Assembly Biosciences News

Here are the key news stories impacting Assembly Biosciences this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $2.28 from $1.90 and maintained a “Buy” rating with a $50 price target, signaling improved expectations for the company’s near-term earnings. HC Wainwright Assembly Biosciences estimates
• Positive Sentiment: The analyst also raised estimates for several periods, including Q3 2026 EPS to a loss of $0.44 from a loss of $0.69, Q1 2027 EPS to positive $0.02 from a loss of $0.16, and FY2027 EPS to a loss of $0.02 from a loss of $0.77. These revisions suggest expectations for a substantially better earnings trajectory.
• Positive Sentiment: Assembly Biosciences was added to Zacks’ Rank #1 (Strong Buy) list and its momentum-focused Strong Buy list. Such rankings may attract momentum-oriented investors, although they are based largely on quantitative factors. Zacks momentum stocks
• Positive Sentiment: Analysts continue to show constructive sentiment: HC Wainwright reiterated its “Buy” rating, while the broader analyst consensus was reported as “Moderate Buy.” Another Zacks analysis cited average analyst price targets implying significant potential upside, while cautioning that price targets are an imperfect forecasting tool. HC Wainwright Buy rating
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $3.19 from $3.69, partially offsetting the broader upward revisions. The company remains dependent on future earnings improvements, and analyst forecasts for some 2027 quarters still call for losses.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.